Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06452719 · ClinicalTrials.gov registry record · Phase 2
Letrozole and Misoprostol for Early Pregnancy Loss Management
A Phase 2 study of Miscarriage and Early Pregnancy Loss, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06452719: Recruiting Phase 2 study of Miscarriage and Early Pregnancy Loss, sponsored by University of Pennsylvania.
NCT06452719 is a Phase 2 study of Miscarriage and Early Pregnancy Loss that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 30 participants, below the 2,092-participant average among 3 other Miscarriage trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06452719, a Phase 2 study of Miscarriage and Early Pregnancy Loss, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot cohort study to preliminarily investigate the efficacy of pretreatment with letrozole 10 mg daily for three consecutive days followed by treatment with misoprostol 800 mcg vaginally for medical management of early pregnancy loss in a US population. Patients will be followed to assess efficacy of this treatment regimen, as well as additional interventions needed, side effects, adverse events, and patient acceptability.
Primary Outcome
Absence of gestational sac on transvaginal ultraound
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Misoprostol
Study Locations (1)
Pennsylvania
- PEACE / Penn Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2026-07-15 |
| Phase | Phase 2 |
What NCT06452719 shows while recruiting
NCT06452719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,092-participant average among 3 other Miscarriage trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Miscarriage appearing as the primary indexed condition, and to 2 interventions - of which Letrozole is the first listed.
NCT06452719 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06452719 about?
NCT06452719 is a clinical study titled "Letrozole and Misoprostol for Early Pregnancy Loss Management". A pilot cohort study to preliminarily investigate the efficacy of pretreatment with letrozole 10 mg daily for three consecutive days followed by treatment with misoprostol 800 mcg vaginally for medical management of early pregnancy loss in a US population. Patients will be followed to assess efficac...
What is the current status of trial NCT06452719?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-08-22. Estimated completion is 2026-07-15.
What conditions does trial NCT06452719 study?
This clinical trial studies the following conditions: Miscarriage, Early Pregnancy Loss, Miscarriage in First Trimester.
What interventions are being tested in trial NCT06452719?
The interventions under investigation include: Letrozole (DRUG), Misoprostol (DRUG).
Who is sponsoring clinical trial NCT06452719?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06452719 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Miscarriage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI